Guida, Linguistica generale, a.a. 2006-07

Questa Guida è stata fatta dalla docente con la collaborazione degli studenti che hanno seguito il corso di Linguistica generale nell'a.a. 2006-07. Una copia cartacea è depositata presso la Biblioteca del Dipartimento di Studi Linguistici e Orientali, via Zamboni 33. Verso la fine delle lezioni dell'a.a. 2007-08 sarà stilata una Guida corrispondente agli argomenti trattati durante il corso e al programma per l'esame di Linguistica generale.

Lezioni di Farmacologia generale per Biotecnologie AA 07-08

Le seguenti lezioni sono da considerare un supporto per la preparazione dell'esame e non escludono l'utilizzo di un libro di testo tra quelli consigliati

Cass. sez. un. 20596-07 Caso oggetto di discussione il 3 aprile 2008

Quesito (entro il 3 aprile 2008): "Il provvedimento del giudice che concede/sospende (ex artt. 648-649 c.p.c.) la provvisoria esecutività del decreto ingiuntivo opposto è sottoponibile a forme di riesame o revocabile?"

Il domicilio digitale può facilitare l'interazione tra il cittadino e la P.A.?

La Legge di conversione n. 221/2012 del Decreto Legge n.79/2012 (c.d. Decreto Crescita 2.0) introduce nel Codice dell’Amministrazione Digitale la facoltà per ogni cittadino di indicare alla pubblica amministrazione un proprio indirizzo di posta elettronica certificata quale suo domicilio digitale. La Legge di conversione n. 98/2013 del Decreto Legge n. 69/2013 (c.d. Decreto del Fare) prevede l’assegnazione di una casella di posta elettronica certificata, con funzione di domicilio digitale, contestualmente al rilascio del Documento Digitale Unificato al cittadino. La disponibilità del domicilio digitale, costituito da una casella di posta elettronica certificata, può consentire alle amministrazioni pubbliche di dematerializzare le comunicazioni verso il cittadino indirizzandole al domicilio digitale con notevoli risparmi dovuti all’eliminazione della carta e delle spese spedizione. In questo studio, attorno al domicilio digitale e alle comunicazioni via posta elettronica certificata, si cercherà di spiegare come e con quali effetti, il diritto di ogni cittadino di disporre di un domicilio digitale possa proficuamente essere esercitato nelle comunicazioni e nelle trasmissioni di documenti con la pubblica amministrazione.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma.

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide. First clinical trials with temozolomide plus bevacizumab therapy in metastatic melanoma patients are ongoing, although the predictive value of the MGMT promoter methylation status in this setting remains unclear. We assessed MGMT promoter methylation in formalin-fixed, primary tumor tissue of metastatic melanoma patients treated with first-line temozolomide and bevacizumab from the trial SAKK 50/07 by methylation-specific polymerase chain reaction. In addition, the MGMT expression levels were also analyzed by MGMT immunohistochemistry. Eleven of 42 primary melanomas (26%) revealed a methylated MGMT promoter. Promoter methylation was significantly associated with response rates CR + PR versus SD + PD according to RECIST (response evaluation criteria in solid tumors) (p<0.05) with a trend to prolonged median progression-free survival (8.1 versus 3.4 months, p>0.05). Immunohistochemically different protein expression patterns with heterogeneous and homogeneous nuclear MGMT expression were identified. Negative MGMT expression levels were associated with overall disease stabilization CR+PR+SD versus PD (p=0.05). There was only a poor correlation between MGMT methylation and lack of MGMT expression. A significant proportion of melanomas have a methylated MGMT promoter. The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints.

Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07)

Abstract This phase II trial treated elderly or frail AML patients with single agent subcutaneous azacytidine at 100 mg/m(2), on 5 of 28 days for up to 6 cycles. Treatment was stopped for lack of response, or continued to progression in responders. Primary endpoint was response within 6 months. A response rate >34% was considered a positive trial outcome. From 9/2008-4/2010, 45 patients from 10 centres (median age 74 (55-86) years) were accrued. Patients received 4 (1-21) cycles. Best response was CR/CRi in 8 (18%; 95% CI: 8%-32%.), 0 (0%) PR, 7 (16%) hematologic improvement, 17 (38%) stable disease. Three nonresponding patients stopped treatment after 6 cycles, 31 patients had stopped early and 11 patients continued treatment for 8-21 cycles. Adverse events (grade >III) were infections (13), febrile neutropenia (14), thrombocytopenia (7), dyspnea (6), bleeding (5) and anemia (4 patients). Median overall survival was 6 months. Peripheral blood blast counts, grouped at 30% had a borderline significant association with response (p = 0.07). This modified azacytidine schedule is feasible for elderly or frail AML patients in an outpatient setting with moderate, mainly hematologic, toxicity and response in a proportion of patients, although the primary objective was not reached.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)

The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer.